Online inquiry

IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5865MR)

This product GTTS-WQ5865MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5865MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5220MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ3739MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ9547MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ15717MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ5009MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ2173MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ5475MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ10098MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW